Related Experiment Video
Updated: Jul 12, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Understanding the drug-eluting stent trials
Alanna Coolong1, Richard E Kuntz
1Division of Cardiology, Brigham and Women's Hospital (a teaching affiliate of Harvard Medical School), Boston, Massachusetts, USA.
Insights
Drug-eluting stents significantly reduce restenosis after coronary angioplasty, even in high-risk patients. These advanced stents deliver medication locally, preventing cellular proliferation and improving outcomes.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
- Interventional Cardiology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) with intravascular stenting has decreased restenosis rates.
- However, restenosis remains a significant concern, particularly in patients with diabetes mellitus or complex lesions.
- Drug-eluting stents (DES) offer a solution by releasing bioactive agents locally to inhibit cellular proliferation.
Purpose of the Study:
- To review the pathophysiology of in-stent restenosis.
- To survey recent clinical trials evaluating the efficacy of drug-eluting stents.
- To highlight the role of DES in managing high-risk patient populations.
Main Methods:
- Review of current literature on the pathophysiology of in-stent restenosis.
- Analysis of key clinical trial data for various drug-eluting stent coatings.
- Discussion of the mechanisms of action for bioactive agents released from stents.
Main Results:
- Drug-eluting stents effectively reduce the incidence of restenosis, even in high-risk patients.
- Sirolimus- and paclitaxel-eluting stents have demonstrated broad efficacy.
- Second-generation DES coatings (everolimus, ABT-578) show promising results in preventing restenosis.
Conclusions:
- Drug-eluting stents represent a significant advancement in preventing restenosis after coronary angioplasty.
- Local drug delivery via DES overcomes limitations of traditional stenting, especially in complex cases.
- Ongoing research and development of new stent coatings continue to improve patient outcomes.
Abstract:
The advent of intravascular stenting dramatically reduced the incidence of restenosis among patients undergoing percutaneous transluminal coronary angioplasty. However, a substantial percentage of patients, particularly those with risk factors such as diabetes mellitus or complicated lesions, remain at risk for restenosis. Drug-eluting stents overcome this problem by releasing bioactive agents from a polymeric coating directly into the vessel wall, inhibiting the cellular mechanisms of restenosis while avoiding systemic toxicity. Recent data indicate that local targeting of the proliferative process with drug-eluting stents dramatically reduces the risk for restenosis, even among high-risk patients. A range of bioactive coatings are currently available or in late clinical trials. Both sirolimus- and paclitaxel-eluting stents have demonstrated efficacy in a broad range of patient types; early data from clinical trials of second-generation stent coatings, such as everolimus and ABT-578 (zotarolimus), suggest that these agents are also effective in preventing restenosis. This article reviews the pathophysiology of in-stent restenosis and surveys recent key clinical trials of drug-eluting stents.
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:30Acute Coronary Syndrome III: Diagnostic Studies